Your Health, We Care
The FIDELITY study showed that the overall incidence of treatment-related adverse events in the finerenone group was comparable to that in the placebo group, with a lower proportion of patients discontinuing treatment due to adverse events.
Finerenone has received consistent high-level recommendations from authoritative guidelines both domestically and internationally due to its clear renal and cardiac benefits, making it an important treatment option for CKD patients related to T2DM.
